Tag: chronic spontaneous urticaria market revenue

Uncover key drivers, emerging technologies, and competitive movements shaping the chronic spontaneous urticaria market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Chronic Spontaneous Urticaria Market from 2026 to 2030?

The chronic spontaneous urticaria market size has demonstrated robust growth in recent years. It is projected to increase from $2.23 billion in 2025 to $2.41 billion in 2026, at a compound annual growth rate (CAGR) of 8.4%. This historical expansion can be attributed to a rising prevalence of chronic skin allergies, the broader availability of second-generation antihistamines, advancements in diagnostic practices, an uptick in dermatology clinic visits, and greater patient awareness regarding urticaria conditions.

The market for chronic spontaneous urticaria is anticipated to experience substantial growth over the coming years. Projections indicate it will reach a value of $3.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.4%. This projected expansion during the forecast period is fueled by factors such as the expanding development pipeline for biologic drugs, heightened investment in autoimmune dermatology research, wider application of targeted monoclonal antibodies, an increasing emphasis on achieving symptom-free disease management, and the greater uptake of long-term maintenance treatments. Key trends expected during this period involve the growing acceptance of biologic therapies for csu, an increase in the utilization of advanced antihistamine protocols, a deepened focus on the underlying mechanisms of autoimmune diseases, the broadening of personalized treatment approaches, and improved monitoring for sustained disease control.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp

What Drivers Are Affecting Demand In The Chronic Spontaneous Urticaria Market?

A rise in alcohol intake is projected to fuel the expansion of the chronic spontaneous urticaria market in the coming period. This elevated alcohol usage stems from multiple elements, including societal customs, pressure, promotional activities, cost-effectiveness, and accessibility. For certain people, ingesting alcohol might worsen the indicators of chronic spontaneous urticaria, resulting in more pronounced hives and puffiness. For example, in 2025, as per the Priory Group, a UK-based provider of mental health, addiction, and specialist education services, a 2023 survey revealed that 25% of UK individuals aged 18–24 now completely abstain from alcohol, showcasing a remarkable trend towards sobriety within the younger demographic. Consequently, the growing intake of alcohol is stimulating the expansion of the chronic spontaneous urticaria market.

Which Segments Are Gaining Traction In The Chronic Spontaneous Urticaria Market?

The chronic spontaneous urticaria market covered in this report is segmented –

1) By Treatment: Medication, Phototherapy, Other Treatments

2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administrations

3) By Diagnosis: Physical Examination, Blood Test, Allergy Test, Other Diagnosis

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Medication: Antihistamines, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Immunosuppressants, Corticosteroids

2) By Phototherapy: UVB Phototherapy, UVA Phototherapy, Narrowband UVB Therapy

3) By Other Treatments: Alternative Therapies, Dietary Modifications, Psychotherapy

Which Innovation Trends Are Advancing Developments Within The Chronic Spontaneous Urticaria Market?

Leading companies within the chronic spontaneous urticaria market are actively engaged in developing advanced next-generation Briquilimab (JSP191) to boost treatment effectiveness and reduce dosing frequency. This next-generation Briquilimab (JSP191) is a monoclonal antibody specifically designed to target and deplete certain immune cells, particularly those expressing CD47, which are implicated in conditions like chronic spontaneous urticaria. For example, in November 2023, Jasper Therapeutics Inc., a US-based clinical-stage biotechnology company, announced it had administered the initial dose to a patient in a Phase 1b/2a clinical study involving Briquilimab for chronic spontaneous urticaria (CSU). This accomplishment marks a vital step in evaluating the safety and effectiveness of Briquilimab, which is a next-generation monoclonal antibody targeting CD47, for treating this recurring issue of hives and itching. The study’s main goal is to ascertain how effectively Briquilimab can ease symptoms and improve the quality of life for patients affected by CSU.

Who Are The Major Companies Operating In The Chronic Spontaneous Urticaria Market?

Major companies operating in the chronic spontaneous urticaria market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Chronic Spontaneous Urticaria Market?

North America was the largest region in the chronic spontaneous urticaria market in 2025. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Chronic Spontaneous Urticaria Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16651&type=smp

Browse Through More Reports Similar to the Global Chronic Spontaneous Urticaria Market 2026, By The Business Research Company

Atopic Dermatitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/atopic-dermatitis-global-market-report

Allergic Rhinitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/allergic-rhinitis-global-market-report

Dermatitis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Is The Chronic Spontaneous Urticaria Market Expected To Grow In Terms Of Size?

The market size for chronic spontaneous urticaria has seen a robust growth in the past few years. The market is expected to rise from a value of $2.06 billion in 2024 to about $2.23 billion in 2025, with a compound annual growth rate (CAGR) of 8.3%. Factors such as advancements in diagnostic tools, increased awareness in the healthcare sector, patient support and advocacy groups, ongoing research and clinical trials for new treatment methods, and heightened healthcare spending have contributed to the growth seen in the historic period.

Expectations are high for robust growth in the chronic spontaneous urticaria market in the coming years, with projections to reach $3.01 billion by 2029, reflecting a compound annual growth rate (CAGR) of 7.9%. The surge expected in the forecast period is due to several factors including a rise in diagnosed CSU cases, an expanding patient base, improved healthcare facilities, a conducive regulatory environment favoring patient-oriented care models, and prosperity in emerging markets. The forecast period also unveils key trends like breakthroughs in technology, enhancements in biological therapy, advancements in personalized medicine, digital health and telemedicine, refined diagnostic tools, the rise of AI and machine learning, and an increase in drug approvals and introductions.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp

Which Key Factors Are Fueling Growth In The Chronic Spontaneous Urticaria Market?

The surge in alcohol intake is expected to drive the expansion of the chronic spontaneous urticaria market. Various factors such as societal pressures, stress, marketing, cost-effectiveness, and accessibility contribute to this increased alcohol consumption. An increase in alcohol intake can considerably worsen chronic spontaneous urticaria symptoms in some people, leading to a rise in hives and skin swelling. For illustration, as reported by rehabs.UK, a UK-based company offering addiction recovery support and counselling services, in February 2024, 55% of men and 41% of women were reported to consume alcohol weekly. Furthermore, 8% of men and 5% of women were reported to consume alcohol nearly every day. Between 2021 and 2022, 342,795 instances of hospital admission were solely due to alcohol-related issues, equating to a rate of 626 admissions per 100,000 individuals. Consequently, the escalating consumption of alcohol is fuelling the growth of the chronic spontaneous urticaria market.

How Is The Chronic Spontaneous Urticaria Market Categorized Across Applications And Types?

The chronic spontaneous urticariamarket covered in this report is segmented –

1) By Treatment: Medication; Phototherapy; Other Treatments

2) By Route Of Administration: Oral; Topical; Parenteral; Other Routes Of Administration

3) By Diagnosis: Physical Examination; Blood Test; Allergy Test; Other Diagnosis

4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users

Subsegments:

1) By Medication: Antihistamines; Leukotriene Receptor Antagonists; Monoclonal Antibodies; Immunosuppressants; Corticosteroids (Oral and Topical)

2) By Phototherapy: UVB Phototherapy; UVA Phototherapy; Narrowband UVB Therapy

3) By Other Treatments: Alternative Therapies; Dietary Modifications; Psychotherapy (for Stress-Related Triggers)

How Are Industry Trends Steering The Expansion Of The Chronic Spontaneous Urticaria Market?

Key players in the chronic spontaneous urticaria market are advancing the progression of next-gen Briquilimab (JSP191), with the goal of heightening treatment effectiveness and minimizing dosing frequencies. This next-generation Briquilimab is a monoclonal antibody that’s manipulated to concentrate on and eradicate particular immune cells, specifically focusing on CD47, associated with chronic spontaneous urticaria. For instance, Jasper Therapeutics Inc., a clinical-stage biotechnology firm based in the US, stated in November 2023 that it initiated dosing for the inaugural patient in a Phase 1b/2a clinical research of Briquilimab for chronic spontaneous urticaria (CSU). This milestone is vital in evaluating the safety and efficacy of this next-generation monoclonal antibody, which is targeting CD47, for combating this recurring hive and itching condition. The research has a goal to quantify how effectively Briquilimab can lessen symptoms and elevate life quality for CSU patients.

Which Firms Are Making The Biggest Impact In The Chronic Spontaneous Urticaria Market?

Major companies operating in the chronic spontaneous urticaria market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

Which Region Holds The Greatest Opportunity For Chronic Spontaneous Urticaria Market Expansion?

North America was the largest region in the chronic spontaneous urticaria market in 2024. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=16651&type=smp

Browse Through More Reports Similar to the Global Chronic Spontaneous Urticaria Market 2025, By The Business Research Company

Chronic Disease Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report

Chronic Lower Back Pain Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report

Chronic Obstructive Pulmonary Disease Copd Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Chronic Spontaneous Urticaria Market By 2029?

The chronic spontaneous urticaria market has experienced substantial growth in recent years. It is anticipated to expand from $2.06 billion in 2024 to $2.23 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.3%. The market’s past growth can be ascribed to advancements in diagnostic tools, increased awareness within the healthcare community, the contributions of patient advocacy and support groups, ongoing research and clinical trials exploring novel therapies, and a rise in healthcare expenditure.

The chronic spontaneous urticaria market is projected to experience substantial expansion over the upcoming years, reaching $3.01 billion by 2029, driven by a compound annual growth rate (CAGR) of 7.9%. This anticipated growth during the forecast period is due to factors such as a rise in diagnosed CSU cases, an expanding patient population, improvements in healthcare infrastructure, a supportive regulatory landscape, the adoption of patient-centric care models, and economic progress in developing markets. Key developments expected during this period involve technological innovations, breakthroughs in biological therapies, personalized medical approaches, the widespread use of telemedicine and digital health, sophisticated diagnostic instruments, the application of AI and machine learning, and an increase in drug approvals and new product introductions.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp

Which Drivers Are Impacting The Chronic Spontaneous Urticaria Market?

Elevated alcohol intake is projected to fuel expansion in the chronic spontaneous urticaria market in the future. This uptick in alcohol intake stems from multiple elements, including societal standards, pressure, promotional activities, cost-effectiveness, and ease of access. For certain people, ingesting alcohol might worsen chronic spontaneous urticaria symptoms, resulting in more pronounced hives and edema. As an illustration, data from February 2024 by rehabs.UK, a UK entity offering addiction recovery aid, indicated that 55% of men consumed alcohol weekly, in contrast to 41% of women. Furthermore, close to daily alcohol consumption was reported by 8% of men, versus 5% of women. Between 2021 and 2022, hospitalizations solely due to alcohol reached 342,795, which equates to a rate of 626 admissions per 100,000 individuals. Consequently, the growing trend of alcohol consumption is a key factor propelling the expansion of the chronic spontaneous urticaria market.

What Are The Segment Types Shaping The Chronic Spontaneous Urticaria Market?

The chronic spontaneous urticariamarket covered in this report is segmented –

1) By Treatment: Medication; Phototherapy; Other Treatments

2) By Route Of Administration: Oral; Topical; Parenteral; Other Routes Of Administration

3) By Diagnosis: Physical Examination; Blood Test; Allergy Test; Other Diagnosis

4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users

Subsegments:

1) By Medication: Antihistamines; Leukotriene Receptor Antagonists; Monoclonal Antibodies; Immunosuppressants; Corticosteroids (Oral and Topical)

2) By Phototherapy: UVB Phototherapy; UVA Phototherapy; Narrowband UVB Therapy

3) By Other Treatments: Alternative Therapies; Dietary Modifications; Psychotherapy (for Stress-Related Triggers)

How Are Emerging Market Trends Shaping The Chronic Spontaneous Urticaria Industry Landscape?

Leading companies in the chronic spontaneous urticaria market are developing advanced next-generation Briquilimab (JSP191) with the goal of improving treatment effectiveness and reducing how often doses are administered. Next-generation Briquilimab (JSP191) is defined as a monoclonal antibody created to specifically target and deplete certain immune cells, particularly those expressing CD47, which are relevant in conditions like chronic spontaneous urticaria. As an illustration, in November 2023, Jasper Therapeutics Inc., a US-based clinical-stage biotechnology company, announced the dosing of its first patient in a Phase 1b/2a clinical study of Briquilimab for chronic spontaneous urticaria (CSU). This achievement marks a crucial step in evaluating the safety and efficacy of Briquilimab, a next-generation monoclonal antibody that targets CD47, in managing this recurring problem of hives and itching. The study aims to assess Briquilimab’s potential to alleviate symptoms and enhance the quality of life for patients suffering from CSU.

Who Are The Prominent Global Companies Shaping The Chronic Spontaneous Urticaria Market?

Major companies operating in the chronic spontaneous urticaria market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

Which Regional Markets Are Contributing Most To The Chronic Spontaneous Urticaria Industry Expansion?

North America was the largest region in the chronic spontaneous urticaria market in 2024. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Chronic Spontaneous Urticaria Market Report:

https://www.thebusinessresearchcompany.com/customise?id=16651&type=smp

Browse Through More Reports Similar to the Global Chronic Spontaneous Urticaria Market 2025, By The Business Research Company

Chronic Disease Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report

Chronic Lower Back Pain Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report

Chronic Obstructive Pulmonary Disease Copd Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has The Chronic Spontaneous Urticaria Market Size Shifted, And What Is the Outlook Through 2034?#_x000D_

The market for chronic spontaneous urticaria has seen robust growth in the past few years. It is projected to increase from $2.06 billion in 2024 to $2.23 billion in 2025, with a compound annual growth rate (CAGR) of 8.3%. Factors contributing to this growth during the historic period include enhanced diagnostic tools, increased awareness within the medical community, patient advocacy and support groups, ongoing research and clinical trials for new treatments, and rising healthcare spending._x000D_

_x000D_

Over the next few years, a substantial increase is projected in the size of the chronic spontaneous urticaria market. It’s forecasted to amplify to $3.01 billion by 2029 at a compound annual growth rate (CAGR) of 7.9%. This growth can be credited to factors such as an upward trend in diagnosed CSU incidents, an expanding patient demographic, the development of healthcare facilities, a conducive regulatory atmosphere encouraging patient-focused care patterns, and an economic upswing in burgeoning markets. Predominant trends for the forecast period encompass technological enhancements, progression in biological therapy, customized medicine, digital health and telemedicine, refined diagnostic tools, the usage of AI and machine learning, along with an escalation in drug approval and introduction._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp_x000D_

_x000D_

#What External and Internal Drivers Are Contributing to the Growth of theChronic Spontaneous Urticaria Market?#_x000D_

The chronic spontaneous urticaria market is slated for expansion, primarily influenced by escalating alcohol intake. The uptick in alcohol consumption can be credited to several determinants such as societal expectations, stress, promotional activities, affordability, and accessibility. In certain individuals, increased alcohol ingestion can intensify symptoms of chronic spontaneous urticaria, resulting in heightened instances of hives and swelling. For example, rehabs.UK, a British organization offering support and advice for combating addiction, indicated in February 2024 that 55% of males and 41% of females admitted to consuming alcohol weekly. Furthermore, 8% of males and 5% of females disclosed daily alcohol indulgence. Between 2021 and 2022, hospitals registered 342,795 admissions linked solely to alcohol use, reflecting a widely-spread issue of 626 admissions per 100,000 inhabitants. Consequently, the amplified consumption of alcohol is fuelling the growth of the chronic spontaneous urticaria market._x000D_

_x000D_

#What Segment Types Define the Chronic Spontaneous Urticaria Market Structure?#_x000D_

The chronic spontaneous urticariamarket covered in this report is segmented – _x000D_

_x000D_

1) By Treatment: Medication; Phototherapy; Other Treatments_x000D_

2) By Route Of Administration: Oral; Topical; Parenteral; Other Routes Of Administration_x000D_

3) By Diagnosis: Physical Examination; Blood Test; Allergy Test; Other Diagnosis_x000D_

4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Medication: Antihistamines; Leukotriene Receptor Antagonists; Monoclonal Antibodies; Immunosuppressants; Corticosteroids (Oral and Topical)_x000D_

2) By Phototherapy: UVB Phototherapy; UVA Phototherapy; Narrowband UVB Therapy_x000D_

3) By Other Treatments: Alternative Therapies; Dietary Modifications; Psychotherapy (for Stress-Related Triggers)_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=16651&type=smp_x000D_

_x000D_

#Which Geographic Areas Hold the Strongest Growth Potential in the Chronic Spontaneous Urticaria Market?#_x000D_

North America was the largest region in the chronic spontaneous urticaria market in 2024. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Long-Term Trends Are Transforming the Competitive Landscape of the Chronic Spontaneous Urticaria Market?#_x000D_

Leading companies in the chronic spontaneous urticaria market are innovating with next-generation Briquilimab (JSP191) to boost the effectiveness of treatments and lessen the need for repeated dosing. This kind of Briquilimab (JSP191) is a tailored monoclonal antibody that targets and depletes certain immune cells, emphasizing on CD47, for conditions such as chronic spontaneous urticaria. For example, in November 2023, the clinical-stage biotech company based in the US, Jasper Therapeutics Inc., announced the beginning of a Phase 1b/2a clinical trial for Briquilimab for chronic spontaneous urticaria (CSU) by dosing its inaugural patient. This progress is pivotal for evaluating the safety and efficacy of Briquilimab, a next-generation monoclonal antibody aimed at CD47, in addressing this persistent hive and itching condition. The purpose of this study is to determine how effectively Briquilimab can ease symptoms and enhance the quality of life for those afflicted by CSU._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report_x000D_

_x000D_

#What Is the Definition of the Chronic Spontaneous Urticaria Market?#_x000D_

Chronic spontaneous urticaria (CSU) is a skin condition characterized by the recurrent appearance of hives (raised, red, itchy welts) and angioedema (swelling) lasting for more than six weeks, without an identifiable external trigger. The exact cause of CSU is often unknown, but it may involve an autoimmune component where the body’s immune system mistakenly attacks healthy skin cells. Treatment focuses on symptom management, primarily using antihistamines and, in more severe cases, other medications such as biologics._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16651_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Market Size of the Chronic Spontaneous Urticaria Market In 2029?

The market size for chronic spontaneous urticaria has exhibited robust growth in the past few years. It is projected to expand from a worth of $2.06 billion in 2024 to $2.23 billion in 2025, showing a compound annual growth rate (CAGR) of 8.6%. The past growth can be ascribed to the advancement in diagnostic tools, increasing consciousness among healthcare providers, patient support and advocacy groups, continuous investigative studies and clinical trials for new treatment options, and rising health care spending.

What Growth Rate Is Forecasted for the Chronic Spontaneous Urticaria Market by 2029?

Over the coming years, the market size of chronic spontaneous urticaria is projected to experience significant expansion. By 2029, it is expected to reach $3.08 billion, with a compound annual growth rate (CAGR) of 8.4%. The sharp rise in the forecast period can be credited to a rise in diagnosed cases of CSU, an expanding patient demographic, advancements in healthcare infrastructure, a supportive regulatory environment, patient-focused care models, and economic progression in emerging markets. Noteworthy trends for the forecast stretch include breakthroughs in technology, progress in biological therapy, personalized healthcare, telemedicine and digital health, high-end diagnostic tools, AI, machine learning, and a surge in drug approvals and introductions.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp

Which Key Companies Are Shaping the Future of the Chronic Spontaneous Urticaria Market?

Major companies operating in the chronic spontaneous urticaria market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.

Which Factors Are Driving Demand in the Chronic Spontaneous Urticaria Industry?

The upward trend of alcohol intake is projected to boost the chronic spontaneous urticaria market’s progress. The growth in alcohol use can be attributed to various factors such as societal standards, stress, advertising, affordability, and accessibility. Drinking alcohol could potentially worsen the symptoms of chronic spontaneous urticaria in certain individuals, leading to an increase in hives and swelling. For example, according to rehabs.UK, a supplier of addiction recovery support and counselling services in the UK, in February 2024, 55% of men were regularly consuming alcohol each week, while the percentage was 41% for women. Also, 8% of male subjects divulged almost daily alcohol consumption, in contrast to 5% of their female counterparts. From 2021 to 2022, related hospital admissions exclusively due to alcohol were 342,795, equating to a rate of 626 admissions per 100,000 individuals. Consequently, the rise in alcohol ingestion is propelling the advancement of the chronic spontaneous urticaria market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=16651&type=smp

How Is the Chronic Spontaneous Urticaria Market Segmented by Several Divisions?

The chronic spontaneous urticaria market covered in this report is segmented –

1) By Treatment: Medication, Phototherapy, Other Treatments

2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administration

3) By Diagnosis: Physical Examination, Blood Test, Allergy Test, Other Diagnosis

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Medication: Antihistamines, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Immunosuppressants, Corticosteroids (Oral and Topical)

2) By Phototherapy: UVB Phototherapy, UVA Phototherapy, Narrowband UVB Therapy

3) By Other Treatments: Alternative Therapies, Dietary Modifications, Psychotherapy (for Stress-Related Triggers)

What are the Emerging Market Trends Driving the Growth of the Chronic Spontaneous Urticaria Industry?

Leading companies in the chronic spontaneous urticaria market are focusing on the creation of next-generation Briquilimab (JSP191) to improve treatment outcomes and minimize dosing intervals. This new generation Briquilimab (JSP191) is a monoclonal antibody created to target and eliminate specific immune cells, mainly those targeting CD47, like in chronic spontaneous urticaria. For illustration, in November 2023, Jasper Therapeutics Inc., a clinical-stage biotech company based in the US, reported that it has administered the first dose to a patient in a phase 1b/2a clinical study of Briquilimab for CSU. This milestone is fundamental in evaluating the safety and effectiveness of Briquilimab, a new-generation monoclonal antibody aimed at CD47, in managing this recurring hive and itch condition. The objective of the study is to determine how well Briquilimab can mitigate symptoms and enhance the life quality of patients affected by CSU.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

Which Regions Are Driving Growth in the Chronic Spontaneous Urticaria Market?

North America was the largest region in the chronic spontaneous urticaria market in 2023. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16651

This Report Delivers Insight On:

1. How big is the chronic spontaneous urticaria market, and how is it changing globally?

2. Who are the major companies in the chronic spontaneous urticaria market, and how are they performing?

3. What are the key opportunities and risks in the chronic spontaneous urticaria market right now?

4. Which products or customer segments are growing the most in the chronic spontaneous urticaria market?

5. What factors are helping or slowing down the growth of the chronic spontaneous urticaria market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the chronic spontaneous urticaria industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Are the Projected Market Size and Growth Rates for the Chronic Spontaneous Urticaria Market From 2025 To 2029?

In recent years, the market size for chronic spontaneous urticaria has seen robust growth. It is projected to increase from $2.06 billion in 2024 to $2.23 billion in 2025, with a compound annual growth rate (CAGR) of 8.6%. This growth during the historical period can be credited to advancements in diagnostic tools, rising knowledge within healthcare circles, the establishment of patient advocacy and assistance groups, ongoing research and clinical trials testing new treatments, and the increase in healthcare spending.

Expectations are high for significant expansion in the chronic spontaneous urticaria market in the coming years, with predictions for it to escalate to a worth of $3.08 billion by 2029, paced by a compound annual growth rate (CAGR) of 8.4%. The predicted growth within this time frame is largely due to factors such as the rise in the number of confirmed CSU cases, an expanding patient base, enhancements in healthcare infrastructure, a supportive regulatory landscape, and patient-focused treatment approaches, not to mention economic progress in emergent markets. Major anticipated trends during this forecast period encompass technological innovation, progress in biological treatments, tailored medicine, the rise of telemedicine and digital health, advanced diagnostics technologies, the application of AI and machine learning, along with an increase in approved and launched drug treatments.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp

What Are the Core Market Drivers Propelling Growth in the Chronic Spontaneous Urticaria Industry?

The chronic spontaneous urticaria market is predicted to expand due to rising alcohol intake. The increased use of alcohol is linked to a variety of factors, including social customs, stress, marketing, affordability, and accessibility. Drinking alcohol may make chronic spontaneous urticaria symptoms worse for some individuals, leading to additional hives and swelling. As an example, according to rehabs.UK, an organisation based in the UK that provides support and guidance for addiction recovery, in February 2024, 55% of males reported drinking alcohol on a weekly basis, as did 41% of females. In addition, 8% of males said they drank nearly daily, compared to 5% of females. Over the course of 2021 to 2022, there were 342,795 hospital admissions directly related to alcohol, equating to a rate of 626 admissions per 100,000 individuals. As a result, the increase in alcohol intake is fuelling the growth of the chronic spontaneous urticaria market.

How Is the Chronic Spontaneous Urticaria Market Segmented?

The chronic spontaneous urticaria market covered in this report is segmented –

1) By Treatment: Medication, Phototherapy, Other Treatments

2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administration

3) By Diagnosis: Physical Examination, Blood Test, Allergy Test, Other Diagnosis

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Medication: Antihistamines, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Immunosuppressants, Corticosteroids (Oral and Topical)

2) By Phototherapy: UVB Phototherapy, UVA Phototherapy, Narrowband UVB Therapy

3) By Other Treatments: Alternative Therapies, Dietary Modifications, Psychotherapy (for Stress-Related Triggers)

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=16651&type=smp

Which Regions Are Driving the Next Phase of the Chronic Spontaneous Urticaria Market Growth?

North America was the largest region in the chronic spontaneous urticaria market in 2023. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in the Chronic Spontaneous Urticaria Market Over the Coming Years?

Leading corporations in the chronic spontaneous urticaria market are engaging in the development of innovative next-gen Briquilimab (JSP191) to amplify the effectiveness of treatment and diminish the necessity for frequent dosing. The term ‘next-generation Briquilimab (JSP191)’ is used to denote a monoclonal antibody engineered to aim at and eliminate certain immune cells, particularly those targeting CD47, in conditions like chronic spontaneous urticaria. In November 2023, Jasper Therapeutics Inc., a clinical-stage biotech company based in the United States, declared that the first patient has received a dosage in a Phase 1b/2a clinical evaluation of Briquilimab for treating chronic spontaneous urticaria (CSU). This milestone marks a significant stride towards determining the safety and efficacy of Briquilimab, a next-gen monoclonal antibody that focuses on CD47, for treating this recurring condition of hives and itching. The research seeks to evaluate the extent to which Briquilimab can assuage symptoms and enhance the quality of life for CSU patients.

View the full report here:

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

How Is the Chronic Spontaneous Urticaria Market Defined and What Are Its Core Parameters?

Chronic spontaneous urticaria (CSU) is a skin condition characterized by the recurrent appearance of hives (raised, red, itchy welts) and angioedema (swelling) lasting for more than six weeks, without an identifiable external trigger. The exact cause of CSU is often unknown, but it may involve an autoimmune component where the body’s immune system mistakenly attacks healthy skin cells. Treatment focuses on symptom management, primarily using antihistamines and, in more severe cases, other medications such as biologics.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16651

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Industry-Specific Factors Are Fueling the Growth of theChronic Spontaneous Urticaria Market?

The growing prevalence of alcohol intake is predicted to spur the expansion of the chronic spontaneous urticaria market in the future. Various elements, such as societal expectations, stress levels, advertising, affordability, and easy access, contribute to the escalating alcohol use. Consuming alcohol may intensify symptoms of chronic spontaneous urticaria for some people, causing more hives and inflammation. For example, rehabs.UK, a UK-based organization providing guidance and support for addiction recovery, found in February 2024 that 55% of males and 41% of females claimed they drank alcohol weekly. Moreover, 8% of males and 5% of females conveyed they consumed alcohol nearly every day. From 2021 to 2022, there were 342,795 hospitalizations entirely due to alcohol, resulting in a rate of 626 admissions per 100,000 individuals. As a result, the surging prevalence of alcohol intake is propelling the expansion of the chronic spontaneous urticaria market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp

What is the Predicted Annual Growth Rate of theChronic Spontaneous Urticaria Market Impact Industry Trends by 2034?

In recent times, the market size of chronic spontaneous urticaria has witnessed robust growth. Its value is projected to increase from $2.06 billion in 2024 to $2.23 billion in 2025 with a compound annual growth rate (CAGR) of 8.6%. The notable growth during the past period is due to enhancements in diagnostic tools, elevated awareness among healthcare professionals, patient advocacy and support groups, continued research and clinical trials for new treatment methods, and the rise in healthcare spending.

Expectations are set for substantial growth in the market for chronic spontaneous urticaria in the coming years, with projections reaching $3.08 billion in 2029 with a CAGR of 8.4%. Several factors are contributing to this positive trend for the forecast period, including a rise in identified CSU cases, an expanding patient demographic, advancements in healthcare facilities, a supportive regulatory context, the adoption of patient-focused care models, and economic advancements in budding markets. Key trends projected for this period consist of technological breakthroughs, progress in biological therapy, the shift towards personalized medicine, the rise of telemedicine and digital health, cutting-edge diagnostic resources, the application of AI and machine learning, and a boom in drug endorsements and launches.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16651

What Key Market Trends and Innovations Are Shaping the Future of theChronic Spontaneous Urticaria Industry?

Leading firms in the chronic spontaneous urticaria market are at the forefront of creating next-level Briquilimab (JSP191), aiming to improve the efficiency of treatments and lessen the need for frequent dosing. Next-level Briquilimab (JSP191) is a type of monoclonal antibody engineered to address and reduce specific immune cells, with a special focus on CD47, associated with chronic spontaneous urticaria. For example, Jasper Therapeutics Inc., a clinical-stage biotechnology company from the US, declared in November 2023 about their progress in a Phase 1b/2a clinical trial of Briquilimab for chronic spontaneous urticaria (CSU), successfully administering the drug to their inaugural patient. This pivotal progress marks a significant stride towards evaluating the safety and efficacy of Briquilimab, a next-level monoclonal antibody focusing on CD47, in tackling this persistent issue of hives and itchiness. The purpose of this trial is to investigate the effectiveness of Briquilimab in mitigating symptoms and upgrading the standard of life for individuals affected by CSU.

Which Companies Are Leading the Charge in Expanding theChronic Spontaneous Urticaria Market Growth?

Major companies operating in the chronic spontaneous urticaria market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

How is the Global Chronic Spontaneous Urticaria Market Segemented?

The chronic spontaneous urticaria market covered in this report is segmented –

1) By Treatment: Medication, Phototherapy, Other Treatments

2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administration

3) By Diagnosis: Physical Examination, Blood Test, Allergy Test, Other Diagnosis

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Medication: Antihistamines, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Immunosuppressants, Corticosteroids (Oral and Topical)

2) By Phototherapy: UVB Phototherapy, UVA Phototherapy, Narrowband UVB Therapy

3) By Other Treatments: Alternative Therapies, Dietary Modifications, Psychotherapy (for Stress-Related Triggers)

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=16651&type=smp

Which Geographics are Influencing the Growth of the Chronic Spontaneous Urticaria Market?

North America was the largest region in the chronic spontaneous urticaria market in 2023. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Chronic Spontaneous Urticaria Market 2025, By The Business Research Company:

Chronic Lower Back Pain Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report

Chronic Pain Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/chronic-pain-global-market-report

Chronic Cough Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/chronic-cough-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: